GC Biopharma

GC Biopharma EBITDA per Share

The EBITDA per Share of GC Biopharma (006280.KS) as of Oct 16, 2026 is 6,058.76 KRW. In the previous year, EBITDA per Share was 4,076.01 KRW — a change of 48.64% (higher).

EBITDA per Share

6,058.76KRW

YoY

48.64%

Last updated:

EBITDA per Share of GC Biopharma is 2025 6,058.76 KRW. EBITDA per Share of GC Biopharma was 2024 4,076.01 KRW. It decreases by 48.64% higher compared to the previous year.

The GC Biopharma EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
4,779.35 KRW
Jan 1, 2019
4,049.74 KRW
Jan 1, 2020
4,986.29 KRW
Jan 1, 2021
7,172.89 KRW
Jan 1, 2022
9,735.27 KRW
Jan 1, 2023
4,077.14 KRW
Jan 1, 2024
4,076.01 KRW
Jan 1, 2025
6,058.76 KRW
The GC Biopharma EBITDA per Share history
YEAREBITDA per ShareYoY
6,058.76KRW+48.64%
4,076.01KRW-0.03%
4,077.14KRW-58.12%
9,735.27KRW+35.72%
7,172.89KRW+43.85%
4,986.29KRW+23.13%
4,049.74KRW-15.27%
4,779.35KRW+118.20%
2,190.35KRW-69.59%
7,201.77KRW-14.33%
8,406.87KRW-4.61%
8,813.21KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GC Biopharma Stock analysis

What does GC Biopharma do? GC Biopharma Corp, headquartered in Yongin, South Korea, operates in the Health Care sector, specifically within Biotechnology. The company manufactures and sells pharmaceutical products such as blood products, vaccines, OTC drugs, diagnostic reagents, cell therapies, and genome analysis services. Listed on 1 August 1989, it serves the South Korean market with a focus on innovative biopharmaceutical solutions. GC Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GC Biopharma stock

EBITDA per Share of GC Biopharma is 6,058.76 KRW in 2025.

EBITDA per Share of GC Biopharma changed from 4,076.01 KRW to 6,058.76 KRW, representing a 48.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share GC Biopharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — GC Biopharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — GC Biopharma